Market capitalization | CHF2.52b |
Enterprise Value | CHF2.72b |
P/E (TTM) P/E ratio | 36.25 |
EV/FCF (TTM) EV/FCF | 161.06 |
EV/Sales (TTM) EV/Sales | 4.83 |
P/S ratio (TTM) P/S ratio | 4.48 |
P/B ratio (TTM) P/B ratio | 7.07 |
Dividend yield | 0.55% |
Last dividend (FY24) | CHF0.69 |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
7 Analysts have issued a Medacta forecast:
7 Analysts have issued a Medacta forecast:
Dec '24 |
+/-
%
|
||
Revenue | 563 563 |
13%
13%
|
|
Gross Profit | 381 381 |
13%
13%
|
|
EBITDA | 152 152 |
17%
17%
|
EBIT (Operating Income) EBIT | 90 90 |
23%
23%
|
Net Profit | 69 69 |
50%
50%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Medacta Group SA engages in the development, manufacture, and distribution of orthopedic and neurosurgical medical devices. The firm offers personalized kinematic models and three-dimensional planning tools for use in hip, knee, shoulder, and spine procedures. It operates through the following geographical segments: Europe, North America, Asia Pacific, and Rest of the World. The company was founded by Alberto Siccardi in 1999 and is headquartered in Castel San Pietro, Switzerland.
Head office | Switzerland |
CEO | Francesco Siccardi |
Employees | 1,907 |
Founded | 1999 |
Website | www.medacta.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.